David Wetherell has spent 20 years as a CEO in high-tech, as well as 17 years in venture capital, the last seven of which have been dedicated to biotech and life sciences. From 1986 to 2006, he served as both CEO and, later, chairman of CMGI, where he helped build the company from $3 million in annual revenues to more than $1 billion and started the first venture capital firm focused on the Internet, @Ventures. In 2003, due to the mapping of the human genome and demographic trends, Wetherell turned his attention to the life sciences.
In 2005, he started GBP Capital, a venture capital company focused exclusively on leading edge life sciences. Wetherell has received numerous awards, including Ernst & Young's New England Entrepreneur of the Year in 2000 and recognition as one of Money Magazine's Top 25 investors. He obtained his B.A. in Mathematics from Ohio Wesleyan University and an honorary doctorate from Bryant University. He currently serves as chairman of Lentigen and sits on the boards of numerous other companies, including HyperMed, Strand, Quintess, and Whiteglove Health.
Douglas Lind joined Biomark Capital in November 2013. Previously he served as Managing Director at Burrill & Company and GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. He has more than 20 years experience in the life sciences industry, ranging from the practice of clinical medicine to work as a top tier Wall Street equity research analyst and venture capitalist. Throughout his career he has focused on identifying promising disruptive technologies and visionary leadership that offer high value solutions to pressing medical needs. He served as senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. His coverage of large and small capitalization biotechnology companies included Amgen, Biogen, Celera (acquired by Quest Diagnostics), Centocor (acquired by Johnson & Johnson), Chiron (acquired by Novartis), IDEC Pharmaceuticals (acquired by Biogen), ImClone (acquired by Bristol-Myers Squibb), MedImmune (acquired by AstraZeneca), Agouron (acquired by Warner Lambert), Axys Pharmaceuticals (acquired by Celera) and Millenium Pharmaceuticals (acquired by Takeda Pharmaceuticals).
Dr. Lind is a graduate of the University of Iowa College of Medicine. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed residency training in internal medicine. He currently serves on the board of directors of Lentigen, and HyperMed Imaging.
Mr. Fong joined Biomark Capital in 2013. Prior to BioMark Capital, Mr. Fong was a Managing Director and General Partner at Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnology industry. Some of Mr. Fong’s recent investments include Pharmasset (VRUS), Novadaq Technologies (NVDQ), Galapagos (GLPG), Ceptaris Therapeutics (acquired by Actelion), and Ferrokin Biosciences (acquired by Shire). Prior to joining Burrill & Company, Mr. Fong held positions as a research scientist with two early stage biotechnology companies located in the San Francisco Bay Area. Mr. Fong currently serves on the Boards of Directors of a number of life science companies including ADMA Biologics (ADMA), NEOS Therapeutics (NEOS), JHL Biotech (6540:TT), and i2Dx. Mr. Fong earned his bachelor's degree with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley.
Sergey Axenovich joined Biomark Capital in November 2013. Before joining Biomark Capital, Dr. Axenovich was a Director at Burrill & Company where he was responsible for sourcing, evaluating, and executing investment transactions. Previously, Sergey managed the cancer drug discovery program and associated corporate collaborations at PPD. He began his research career at Genome Therapeutics. Subsequently, he received his MBA from the University of California, Berkeley Haas School of Business. Sergey has a Ph.D. in Molecular Genetics from the University of Illinois, Chicago and an undergraduate degree in Molecular Biology from Moscow University.
Joshua Zelig joined Biomark Capital in November 2013. Prior to joining the Company, Mr. Zelig was a Director at Burrill & Company and an Associate Partner at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. In that capacity he was responsible for sourcing, evaluating, and executing investment transactions and new business opportunities. Additionally, Mr. Zelig managed the firm’s intellectual property portfolios, oversaw the company’s operations, and worked closely with portfolio companies in setting and delivering strategic objectives.
Previously, Mr. Zelig was an Equity Research associate at Morgan Stanley where he covered biotech and consumer stocks. He later worked in real estate management, acquisition, and due diligence on behalf of a number of large private real estate companies as well as public REITs.
Mr. Zelig is a graduate of Yeshiva University, Sy Syms School of Business, where he received a Bachelor of Science in Finance.
Dr. Redei is an Entrepreneur-in-Residence with two decades of experience in healthcare technology, the pharmaceutical industry, and academia; he is also Co-Founder and CTO of i2Dx, Inc., a Neuro-focused Big Data Analytics company. Dr. Redei is a former University of California, San Francisco faculty member and holds an M.D., as well as a Ph.D. in Applied Neuroinformatics. He comes to Biomark Capital following stints at Burrill & Company and Roche/Genentech, a leader in personalized healthcare.
Previously Dr. Redei headed clinical and imaging informatics at Roche for all six therapeutic areas globally, including CNS. At Roche, he was instrumental in developing a number of group-wide emerging IT strategies and implemented the company’s first forays into on-demand/cloud computing for clinical applications, and digital health. He also led the informatics effort of a consortium of five pharma companies to enable disease understanding, incorporating biosample, imaging, and clinical data sources from around the globe.